All companies
Visit website
Ortek Therapeutics
OperatingOrtek Therapeutics, Inc.
Healthcare · Founded 1998
Setting a new standard for optimal oral health
Post-money valuation ⓘ
$22.8M
As of Sep 2022 · from Ortek Therapeutics Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$62,593
Across 1 round since 2022
Latest share price
$1.00
Ortek Therapeutics Common Stock 1 offering price
Financials
FY2020–FY2022 · from SEC filings · hover any figure for its source$2.1M
−$230K
2020
$445K
−$615K
2021
$467K
−$594K
2022
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020
FY2021
FY2022
Income statement
Revenue
$2,145,578
$445,252
$466,824
Cost of goods sold
$1,174,308
$112,341
$169,880
Gross margin
45%
75%
64%
Net income
-$230,189
-$614,548
-$594,439
Taxes paid
$0
$0
$0
Balance sheet
Cash
$1,547,649
$981,561
$462,038
Accounts receivable
$931,347
$0
$0
Total assets
$2,014,889
$1,406,235
$885,240
Short-term debt
$22,638
$0
$0
Long-term debt
$0
$0
$0
Total liabilities
$22,638
$0
$0
Other
Headcount
—
2
2
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$22.8M
post-money
Ortek Therapeutics Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $62.6K / $1.1MInvestors 78Post-money $22.8M
Reg CF annual-report compliance
Not requiredFiled Form C-TR (terminated reporting)
Filed 1 of 4 annual reports (FY2022–FY2025)
78 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001070105Share price $1.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.